Latest Insider Transactions at Kiniksa Pharmaceuticals, Ltd. (KNSA)
This section provides a real-time view of insider transactions for Kiniksa Pharmaceuticals, Ltd. (KNSA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kiniksa Pharmaceuticals, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kiniksa Pharmaceuticals, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 10
2023
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,933
-6.45%
|
$29,330
$10.71 P/Share
|
|
Apr 10
2023
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,992
+18.0%
|
-
|
|
Apr 10
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
734
-1.72%
|
$7,340
$10.71 P/Share
|
|
Apr 10
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,498
+5.53%
|
-
|
|
Apr 10
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,353
-9.73%
|
$13,530
$10.71 P/Share
|
|
Apr 10
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,477
+15.12%
|
-
|
|
Apr 10
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,155
-8.17%
|
$11,550
$10.71 P/Share
|
|
Apr 10
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,933
+21.77%
|
-
|
|
Apr 10
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-0.66%
|
$8,010
$10.71 P/Share
|
|
Apr 10
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,727
+2.21%
|
-
|
|
Mar 20
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,078
-2.62%
|
$11,858
$11.12 P/Share
|
|
Mar 20
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,671
+8.18%
|
-
|
|
Mar 20
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
634
-6.07%
|
$6,974
$11.12 P/Share
|
|
Mar 20
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,158
+17.12%
|
-
|
|
Mar 20
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
876
-0.74%
|
$9,636
$11.12 P/Share
|
|
Mar 20
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,982
+2.44%
|
-
|
|
Mar 20
2023
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,523
-9.02%
|
$38,753
$11.12 P/Share
|
|
Mar 20
2023
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,002
+23.51%
|
-
|
|
Mar 20
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
635
-5.86%
|
$6,985
$11.12 P/Share
|
|
Mar 20
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,163
+16.64%
|
-
|
|
Mar 20
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-9.26%
|
$12,837
$11.12 P/Share
|
|
Mar 20
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,137
+14.5%
|
-
|
|
Mar 16
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
507
-1.33%
|
$5,577
$11.46 P/Share
|
|
Mar 16
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+4.34%
|
-
|
|
Mar 16
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
256
-3.0%
|
$2,816
$11.46 P/Share
|
|
Mar 16
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
872
+9.26%
|
-
|
|
Mar 16
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
577
-0.49%
|
$6,347
$11.46 P/Share
|
|
Mar 16
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+1.66%
|
-
|
|
Mar 16
2023
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,929
-6.66%
|
$21,219
$11.46 P/Share
|
|
Mar 16
2023
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+18.49%
|
-
|
|
Mar 16
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
221
-2.49%
|
$2,431
$11.46 P/Share
|
|
Mar 16
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
774
+8.01%
|
-
|
|
Mar 16
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
543
-4.94%
|
$5,973
$11.46 P/Share
|
|
Mar 16
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
994
+8.29%
|
-
|
|
Jan 15
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
704
+7.98%
|
$6,336
$9.56 P/Share
|
|
Jan 15
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,844
+15.56%
|
$16,596
$9.56 P/Share
|
|
Nov 29
2022
|
Barry D Quart |
SELL
Open market or private sale
|
Direct |
21,959
-100.0%
|
$351,344
$16.15 P/Share
|
|
Nov 29
2022
|
Barry D Quart |
BUY
Exercise of conversion of derivative security
|
Direct |
21,959
+50.0%
|
$21,959
$1.59 P/Share
|
|
Nov 07
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
28,357
-43.83%
|
$425,355
$15.18 P/Share
|
|
Nov 07
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
28,357
+30.48%
|
$28,357
$1.86 P/Share
|
|
Oct 04
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
52
-0.7%
|
$728
$14.23 P/Share
|
|
Oct 04
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
175
+2.29%
|
-
|
|
Sep 02
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
563
-6.45%
|
$6,193
$11.44 P/Share
|
|
Sep 02
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
995
+10.23%
|
-
|
|
Sep 02
2022
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,929
-7.93%
|
$21,219
$11.44 P/Share
|
|
Sep 02
2022
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+21.26%
|
-
|
|
Sep 02
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
507
-1.38%
|
$5,577
$11.44 P/Share
|
|
Sep 02
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+4.47%
|
-
|
|
Sep 02
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
547
-6.66%
|
$6,017
$11.44 P/Share
|
|
Sep 02
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,861
+18.46%
|
-
|